苏州大学药学院欢迎您!

[12-6]东吴药学论坛系列讲座 | 韩国学术报告专场

发布者:金雪明发布时间:2019-11-29浏览次数:10

报告一

报告题目:Mechanistic Understanding for Solubilization and Controlled Release of Poorly Water-soluble Drugs in Solid Dispersions via Self-assembled Nanonization Process

报告人:Beom-Jin Lee, Professor, Ajou University, South Korea

报告时间:2019.12.06 (Friday), 15:00-17:00

报告地点:2301 Yunxuan Building


报告人简介:Beom-Jin Lee is the Dean of, and full professor in, the College of Pharmacy, Ajou University. He was awarded his BSc and MSc from the College of Pharmacy, Seoul National University, Republic of Korea, and his PhD from the College of Pharmacy, Oregon State University, Corvallis, USA. His research interests include pharmaceutical sciences and drug development focusing on the “i) Controlled bioavailability of poorly soluble and poorly absorbable drugs; ii) Solubilization, formulation and development of patient-centered drug delivery system; iii) Advanced nano-based delivery systems using fattigation (fatty acid conjugation) and click chemistry in a biomimetic condition, iv) Narcotic issues and abuse-deterrent system, v) Pharmacy practice and outcome based education system”. He has authored 200 peer-reviewed papers, 28 book chapters, and numerous oral and poster presentations. He has received more than 35 outstanding achievement awards from government and other organizations. He is currently president of the Asian Association of Schools of Pharmacy (AASP) and Immediate President of Korean Society of Pharmaceutical Science and Technology (KSPST), and Academic Institution Members (AIM) advisory committee and a delegate of the International Pharmaceutical Federation (FIP). He also serves as an editorial board member of several peer-reviewed journals.


报告摘要:The poor aqueous solubility and dissolution rate of API is one of the biggest challenges in pharmaceutical research and development. Various pharmaceutical approaches to overcome the poor aqueous solubility of drug candidates have been investigated in drug research and development such as salt formation, prodrug formation, particle size reduction, complexation, micelles, microemulsions, nanoemulsions, nanosuspensions, solid–lipid nanoparticle and solid dispersion (SD). Among them, SD as defined as a dispersion of one or more API in an inert carrier or matrix at the solid state prepared by solvent, melting or solvent–melting method is considered one of the most successful strategies in terms of enhanced solubility and reliable bioavailability and successfully classified four categories, depending on physicochemical properties of drugs in SD systems. The solubilization mechanism include drug crystallinity, powder properties, microenvironmental pH and intermolecuar interaction. The insoluble drug particles are able to be readily nanonized due to these effect.

Furthermore, controlled release (CR) of SD systems offer several medical advantages, such as reducing the adverse effects, dosing frequency and ultimately enhancing the patient compliance of various poorly water-soluble drugs, giving enhanced dissolution rate in a controlled manner for optimal therapy. Recently, macromolecules (gelatin, albumin) and fatty acid (oleic acid, stearic acid) were conjugated to develop a natural solubilizing adjuvant using the fattigation platform technology to enhance solubility and dissolution rate of poorly water-soluble drugs according to self-assembly and nanonization principle when simply mixed with poorly water-soluble drugs.

In this presentation, we will address solubilization mechanism of poorly water-soluble drugs via 1) modified physicochemical properties of drug in SD; 2) nanomization process and its modulation for controlled release and 3) use of amphiphilic conjugates via self-assembly.

  

报告二

报告题目:Organ on Chip Systems with Integrated Biosensors for Cytotoxicity Evaluation of Drug Compounds

报告人:Kyung Hyun Choi, Professor, Jeju National University, South Korea

报告时间:2019.12.06 (Friday), 15:00-17:00

报告地点:2301 Yunxuan Building


报告人简介:Professor Kyung Hyun Choi received PhD from University of Ottawa, Canada. He is currently working as Professor in Department of Mechatronics Engineering at Jeju National University. He is leading the multi-disciplinary Advanced Micro Mechatronics (AMM) lab since 2005. A vast variety of electronic materials are developed and used in device fabrication using state of the art in-house developed micro/nano patterning and film deposition printed electronics systems. In his lab, the main research projects focus on Bioprinting, Lab-on-a-chip, Organ-on-a-Chip and Tissue Engineering. Recently, the group has successfully developed organ-on-a-chip platforms with real-time sensor integration. The embedded sensors have been reliably implemented for the online monitoring of Liver-on-a-chip, Lung and Breast Cancer-on-a-Chip and Kidney-on-a-Chip platforms for development of disease and drug testing for specific organ.


报告摘要:Many organ on chip systems have been used for successfully mimicking the in-vivo micro physiological environment so far. However there is still room for integrating reliable and authenticated technologies to make them a standard tool for preclinical cytotoxicity evaluation of drug candidates both biological as well as synthetic. Organ on chip systems with integrated biosensors have proven their usefulness in drug toxicity assessment. On chip physiological monitoring like pH sensing, dissolved oxygen (DO) monitoring, and cell viability assessment using trans-epithelial electrical (TEER) impedance monitoring in real time have played a key role among various other integrated sensing technologies. Apart from the above mentioned physiological sensors, cellular release or uptake of certain biomarkers upon treatment with certain drug compounds can be monitored in real time using integrated microfluidic electrochemical biosensors. Not only single but multi organ models have also been evaluated using integrated biosensors to study the toxicity effects in organ crosstalk. Thus a multi organ on chip system with integrated physiological and pathological biosensors can be used as a promising tool to study the preclinical toxicity of drug candidates instead of animal testing in near future. Not only it will aid the traditional drug development pipeline but can also be used for personalized medicine applications